Pelvital – a leading innovator in women’s health – recently announced closing a $2.68 million seed funding round for Flyte, an accessible and clinically proven treatment for stress urinary incontinence (SUI) and weakened pelvic floor muscles. This funding milestone emphasizes Flyte’s significant impact in addressing an underserved health concern among women.
Flyte is considered the only at-home intravaginal device that delivers the proven treatment modality of mechanotherapy to treat SUI and strengthen pelvic floor muscles quickly and effectively.
Flyte is considered a first-of-its-kind, non-invasive, intravaginal at-home device designed for the strengthening of pelvic floor muscles, which has been found to help stress urinary incontinence. And Flyte was originally developed by physicians from the Arctic University of Norway in collaboration with experts in gynecology, muscle rehabilitation, and urinary incontinence treatments. Plus, Flyte’s mechanism of action is mechanotherapy, a foundational treatment modality that when paired with an active pelvic floor contraction, stimulates tissue repair and the creation of neuromuscular memory.
This investment round was led by Boomerang Ventures, a venture firm focused on transformative connected health. And other participants in the round include VisionTech Partners, Wisconsin Investment Partners, and Edward Bergmark, Ph.D., Founder and former CEO of Optum.
The seed funding round will be used to complete the development of the company’s next-generation product and to accelerate commercialization, expanding its reach to a broader audience of clinicians and women seeking an effective, convenient, conservative in-home treatment for stress urinary incontinence. And two clinical trials studied the safety, efficacy, and durability of Flyte in women with SUI. These studies demonstrated that Flyte delivers continence rates and durability comparable to surgery, yet with a conservative, fast, and convenient treatment.
Flyte is effective for mild, moderate, and severe SUI. And typical treatment is only five minutes per day for a total of six weeks. Flyte is FDA-cleared for both over-the-counter and prescription use.
KEY QUOTES:
”Pelvital is committed to empowering both women and clinicians with transformative products backed by strong clinical evidence. We are excited to partner with Boomerang as we execute on our vision to be the gold standard of care for treatment of urinary incontinence, an issue that impacts one in two women. Boomerang’s focus on transformative healthcare technology is a perfect match as we introduce our next generation product to the clinical community. In the context of significant gaps in health equity – and in particular for issues that disproportionately impact peri-menopausal and menopausal women – increasing access to clinically proven, patient-centric treatments is vitally important.”
— Lydia Zeller, President and CEO of Pelvital
“Boomerang Ventures is driven to solve the biggest challenges in healthcare which is why we’re so excited about this investment in Flyte by Pelvital. Their commitment to innovation, science-backed results, research and development, and user experience is making a significant impact on lives and on the cost of care. We have understood for a long time both the opportunity and the historic underfunding in women’s health care, and we’re beginning to understand how largely neglected the menopause segment is. We are incredibly proud to be part of the contingent addressing this gap.”
— Oscar Moralez, Founder and Managing Partner of Boomerang Ventures
